Followers | 33 |
Posts | 2641 |
Boards Moderated | 0 |
Alias Born | 02/18/2005 |
Monday, October 24, 2022 12:38:13 PM
Recent SHPH News
- Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE • GlobeNewswire Inc. • 07/19/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:59:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 01:00:15 PM
- Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer • GlobeNewswire Inc. • 06/18/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/10/2024 10:12:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:15:20 PM
- Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • GlobeNewswire Inc. • 05/22/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 01:00:22 PM
- Shuttle Pharma Provides First Quarter 2024 Corporate Update • GlobeNewswire Inc. • 05/14/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 09:01:59 PM
- Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 • GlobeNewswire Inc. • 04/23/2024 08:15:00 PM
- Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update • PR Newswire (US) • 03/22/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 11:18:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 02:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:00:16 PM
- Shuttle Pharma Announces Its Intent to Pursue a Rights Offering • PR Newswire (US) • 02/13/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:25:13 PM
- Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 • PR Newswire (US) • 01/23/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:05:10 PM
- Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma • PR Newswire (US) • 01/08/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:10:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 02:51:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 10:10:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 02:00:12 PM
- Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma • PR Newswire (US) • 12/11/2023 02:00:00 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM